Opinions The Panic-Proof Portfolio (Stockchase Research)
Cullinan Oncology, Inc.CGEMTOP PICKMar 09, 2023
N/A
Stock price when the opinion was issued
$17.65
As of Jun 24, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
(A Top Pick Jun 06/23, Down 30.8%)Stockchase Research Editor: Michael O’Reilly
Our PAST TOP PICK with CGEM has triggered its stop at $8.50. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 27%, when combined with previous recommendations.
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly
We reiterate this biopharma company focused on oncology therapies, as a TOP PICK. Pilot projects are continuing to advance and they have a growing pipeline of new prospects. It trades under book value, supporting a 14% ROE. Cash reserves are growing, while debt is retired. We recommend maintaining the stop at $8.50, looking to achieve $17.00 -- upside of 36%. Yield 0%
(Analysts’ price target is $29.00)biotechnologypharmaceutical
CGEM is a unique pharmaceutical company that collaborates with other developers and academia to develop drugs to help cancer patients. It has six on-going products in its pipeline. It trades below book value, at 6x earnings, and supports a 19% ROE. We like that it is low beta compared to the market. We recommend a stop-loss at $8.50, looking to achieve $17 — upside potential of 50%. Yield 0%
(Analysts’ price target is $28.75)